{"nctId":"NCT00296322","briefTitle":"Trial of Adjuvant Chemotherapy for Gastric Cancer","startDateStruct":{"date":"2001-10"},"conditions":["Stomach Cancer"],"count":528,"armGroups":[{"label":"Mitomycin-C, Doxifluridine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: cisplatin, mitomycin-C, doxifluridine"]},{"label":"Mitomycin-C, Doxifluridine, Cisplatin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: cisplatin, mitomycin-C, doxifluridine"]}],"interventions":[{"name":"cisplatin, mitomycin-C, doxifluridine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pathologically proven gastric adenocarcinoma\n* Grossly serosa invasion of primary tumor is suspicious\n* Curative resection was done\n* Stage II, IIIA, IIIB, IV (including T4, lesions or N3, but excluding M1 lymph node metastasis)\n* Age: 18-69 years old\n* Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2\n* Adequate bone marrow function (white blood cell counts ≥ 4,000/ul, platelet count ≥ 100,000/ul, hemoglobin ≥ 10 g/dl)\n* Adequate renal function (serum creatinine≤ 1.5)\n* Adequate liver function (serum bilirubin ≤1.5 mg/dl, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 x normal upper limit)\n* Written informed consent was signed by the patient\n\nExclusion Criteria:\n\n* Previous chemotherapy or radiotherapy\n* Active ongoing infection which antibiotic treatment is needed\n* Pregnant or lactating women\n* Psychosis or convulsion disorder\n* Ascites in preoperative abdomen computed tomography (CT)\n* Systemic disease which interfere the administration of chemotherapy\n* Postoperative pathologic stage IA, IB\n* Postoperative pathology indicates that resection margin is involved\n* Previous history of other malignancy except cured non-malignant skin cancer and uterine cervical cancer in situ","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"69 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Relapse-free Survival","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"60.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Toxicity Profile (According to NCI CTC Version 2.0)","description":"Because safety profile in oncology study is evaluated for each toxicity, it is impossible to present the overall patient number. Instead, we presented the number of patients who declined study therapy due to adverse events or patient will.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.6","spread":null},{"groupId":"OG001","value":"71.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":258},"commonTop":["Anemia","Fatigue","Anorexia","Nausea","Neutropenia"]}}}